{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T07:06:02Z","timestamp":1784185562347,"version":"3.55.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jiac.2026.103012","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:37:10Z","timestamp":1781023030000},"page":"103012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Results of three multicenter observational studies of regimens containing tenofovir alafenamide among people with HIV in Japan"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1213-0949","authenticated-orcid":false,"given":"Nao","family":"Taguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Ohnishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Ohwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Serejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4879-8756","authenticated-orcid":false,"given":"KuanYeh","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Ishizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5430-0955","authenticated-orcid":false,"given":"Jami","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2026.103012_bib2","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jiac.2021.02.003","article-title":"Changes in survival and causes of death among people living with HIV: three decades of surveys from Tokyo, one of the Asian metropolitan cities","volume":"27","author":"Tsuda","year":"2021","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2026.103012_bib3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/hiv.13206","article-title":"Comorbidities and co-medications among 28 089 people living with HIV: a nationwide cohort study from 2009 to 2019 in Japan","volume":"23","author":"Naito","year":"2022","journal-title":"HIV Med"},{"key":"10.1016\/j.jiac.2026.103012_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/hiv.13460","article-title":"Long-term success for people living with HIV: a framework to guide practice","volume":"24","author":"Lazarus","year":"2023","journal-title":"HIV Med"},{"key":"10.1016\/j.jiac.2026.103012_bib7","series-title":"EACS guidelines","year":"2023"},{"key":"10.1016\/j.jiac.2026.103012_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/13596535211067600","article-title":"Tenofovir alafenamide fumarate","volume":"27","author":"Lee","year":"2022","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jiac.2026.103012_bib9","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2026.103012_bib10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/15284336.2019.1589232","article-title":"Efficacy and safety of elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: a sub-analysis of phase 3 clinical trials","volume":"20","author":"Kim","year":"2019","journal-title":"HIV Res Clin Pract"},{"key":"10.1016\/j.jiac.2026.103012_bib11","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/QAI.0000000000001344","article-title":"Brief report: long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically suppressed adults","volume":"75","author":"Raffi","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiac.2026.103012_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1187999","article-title":"Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study","volume":"13","author":"Santos","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jiac.2026.103012_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101991","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials","volume":"59","author":"Sax","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jiac.2026.103012_bib14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40780-024-00336-y","article-title":"Renal function and lipid metabolism in Japanese HIV-1-positive individuals 288 weeks after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate: a single-center, retrospective cohort study","volume":"10","author":"Abe","year":"2024","journal-title":"J Pharm Health Care Sci"},{"key":"10.1016\/j.jiac.2026.103012_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0313338","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) in treatment-naive and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort","volume":"20","author":"Yokomaku","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.jiac.2026.103012_bib16","article-title":"Real-world effectiveness, safety, and health-related quality of life in people living with HIV receiving bictegravir\/emtricitabine\/tenofovir alafenamide-12-month results of the BICSTaR French cohort","volume":"16","author":"Hocqueloux","year":"2025","journal-title":"IJID Reg"},{"key":"10.1016\/j.jiac.2026.103012_bib17","first-page":"407","article-title":"Effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in people with HIV: a real-world data from the Spanish BICSTaR cohort","volume":"17","author":"Inciarte","year":"2025","journal-title":"HIV AIDS (Auckl)"},{"key":"10.1016\/j.jiac.2026.103012_bib18","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jmii.2024.07.003","article-title":"Twelve-month effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in treatment-na\u00efve and treatment-experienced people with HIV: findings from the Asia cohort of the BICSTaR study","volume":"57","author":"Tseng","year":"2024","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jiac.2026.103012_bib19","series-title":"20th European AIDS Conference 2025","first-page":"138","article-title":"Five-year extended follow-up of the observational BICSTaR cohort: final analysis in people with HIV (PWH) receiving bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) in routine clinical practice","author":"De Wet","year":"2025"},{"key":"10.1016\/j.jiac.2026.103012_bib20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.24875\/AIDSRev.19000023","article-title":"Neuropsychiatric adverse events with dolutegravir and other integrase strand transfer inhibitors","volume":"21","author":"Hoffmann","year":"2019","journal-title":"AIDS Rev"},{"key":"10.1016\/j.jiac.2026.103012_bib21","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/hiv.12784","article-title":"Evaluation of kidney function in HIV-infected patients receiving an antiretroviral regimen containing one or two inhibitors of the tubular secretion of creatinine","volume":"20","author":"Casado","year":"2019","journal-title":"HIV Med"},{"key":"10.1016\/j.jiac.2026.103012_bib22","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/cid\/ciae191","article-title":"Antiretrovirals and weight change: weighing the evidence","volume":"79","author":"Wohl","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2026.103012_bib23","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/jvh.13912","article-title":"Real-world safety and effectiveness of tenofovir alafenamide for 144 weeks in Japanese patients with chronic hepatitis B","volume":"31","author":"Hige","year":"2024","journal-title":"J Viral Hepat"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X26001108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X26001108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T06:33:46Z","timestamp":1784183626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X26001108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1341321X26001108"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2026.103012","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of three multicenter observational studies of regimens containing tenofovir alafenamide among people with HIV in Japan","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2026.103012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103012"}}